Sandostatin® (octreotide acetate) is the only somatostatin analogue available to treat severe diarrhea and flushing associated with carcinoid syndrome.* 1,2
This section will highlight some of the benefits of Sandostatin®, including:
- Control that is unparalleled with Sandostatin®
- Trust in the therapy with over 20 years of clinical experience
Unparalleled control with Sandostatin®
Sandostatin® is a somatostatin analogue, and the only approved medical therapy for the control of the severe diarrhea and flushing associated with carcinoid syndrome. It works directly at the site of the carcinoid tumors to help decrease the production of hormones that lead to the severe diarrhea and flushing associated with carcinoid syndrome.1,2
Two formulations, one therapy2,3
While both of these treatments contain the same drug—octreotide acetate—they are each administered differently.
- Prior to beginning treatment with Sandostatin® LAR Depot, some patients may be started on 2 weeks of Sandostatin® (octreotide acetate) Injection
- While a patient is on Sandostatin® LAR Depot, periodic symptom flare-ups can be treated with Sandostatin® Injection
According to the National Comprehensive Cancer Network, patients who are experiencing severe diarrhea and flushing associated with carcinoid syndrome should be started on octreotide to address these symptoms.4
Trust in over 20 years of clinical experience
Sandostatin® offers you:
- Confidence and reliability of over 5 million doses of Sandostatin® LAR Depot administered worldwide†5
- More than 20 years of unparalleled evidence, established through2,5,6
*Includes both formulations – injection and LAR Depot.
† For all approved indications.
‡ Sandostatin® Injection and Sandostatin® LAR Depot for all approved indications.
§Includes both ongoing and completed trials for all approved indications.
INDICATIONS AND USAGE
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is a prescription medicine indicated for patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for:
- Long-term maintenance therapy in acromegalic patients who have had inadequate response to surgery and/or radiotherapy or for whom surgery and/or radiotherapy is not an option (the goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal).
- Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
- Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors
In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases has not been determined.
IMPORTANT SAFETY INFORMATION
Warnings and precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, sugar metabolism, thyroid and heart function, and nutritional absorption, which may require monitoring by your doctor.
Before taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.
Common side effects: Most patients experience side effects at some time. Some common side effects you may experience include:
- Acromegaly: diarrhea, gallstones, abdominal pain, and flatulence
- Carcinoid tumors: back pain, fatigue, headache, abdominal pain, nausea, and dizziness
Other information: Patients with carcinoids tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms. Patients with acromegaly should adhere to their return visit schedule to help assure steady control of GH and IGF-1 levels.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
